Program
evenamide hydrochloride
Also written as “Evenamide”, “Evenamide 15 mg bid” and “NW-3509a”.
Its studies are mostly in Schizophrenia · Schizophrenia, Treatment-Resistant, led by Newron Pharmaceuticals SPA.
Furthest: phase 3, since Sep 18, 20255 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Newron Pharmaceuticals SPA | 51 open or running | phase 3since Sep 18, 2025 | Aug 21, 2013 | Mar 31, 2027phase 3 · NCT07184619 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2013First study: phase 1 study in SchizophreniaFirst studyNCT01955564 · 54 enrolled · United States
- Nov 20, 2015Phase 2 study in Chronic SchizophreniaNCT02624167 · 90 enrolled · United States, India
- Jan 29, 2018Phase 1 study in HealthyNCT03446274 · 6 enrolled · United Kingdom
- Jun 19, 2020Phase 2 study in SchizophreniaNCT04461119 · 138 enrolled · United States, India
- Sep 18, 2025Phase 3 study in Schizophrenia, Treatment-ResistantNCT07184619 · 400 planned · United States, Argentina, Colombia and more
Ahead
- Mar 31, 2027Primary completion: phase 3 study in Schizophrenia, Treatment-ResistantNCT07184619
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07184619Schizophrenia, Treatment-Resistant · United States, Argentina, Colombia and more | 3 | Recruiting | Mar 31, 2027 | 400 |
| NCT04461119Schizophrenia · United States, India | 2 | Completed | Feb 20, 2021 | 138 |
| NCT03446274Healthy · United Kingdom | 1 | UNKNOWN | Apr 23, 2018 | 6 |
| NCT02624167Chronic Schizophrenia · United States, India | 2 | Completed | Dec 2016 | 90 |
| NCT01955564Schizophrenia · United States | 1 | Completed | Sep 2014 | 54 |
How it is read
Names in the registry
- “Evenamide”, 2 entries
- “Evenamide 15 mg bid”, 1 entry
- “NW-3509a”, 1 entry
- “NW-3509A”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 3 studies
- Schizophrenia, Treatment-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.